Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He's also Chief Executive Officer and Director of BioMedical Technology Solutions Holdings, Inc. since April 30, 2014.
That stock, BMTL, was delisted a few months after he took over. At least those holders are DONE being screwed!
I responded to your post. Yea, I'd call F&Co "Mom's basement" at this point, for sure I get the feeling you bought, though. Probably not much in the way of comeuppance, eh?
Guess we'll hear something eventually. GLTA
Precisely RDY! The real DD was done by those who hold the shares!
Just go ahead and read those posts:
"Shortly afterward he purchased a position in NEOM. Why would he do that if he was already invested in Keyon?"
What does one have to do with the other?
"There is only 1 institutional holder and it is not California Capital Equity. They are also not on the insider roster."
It's a form 15-12G SHELL!
"When is the last time anyone tried to access www.keyon.com. I get an error. Does this company even exist anymore?"
NO! IT'S A FORM 15-12G SHELL!!!!!!!!!!!!
KEYO
§KEYO DD costs $$ DE Status§
http://www.sugareestitches.com/temp/NantworksLLCStatus14-10-28.htm
KEYO
ELRA Again? Like a money tree!
§ELRA
He certainly won't return my calls. The only chance I have there is getting through direct at F&Co when Betty's at lunch. gave up on that long ago. Delist comes May next year. I'll piddle my way out by then. Sad Sad Sad.
§NLEF
Yea, I've been busy. But I'll call Kinder and Eppel. It's painfully clear that there are those who want their money, and he was hired to get it for them. Screw us, as usual. Ob-La-De Ob-La-Da...life goes on, bra!
§NLEF
§KEYO HAPPY 5000 KEYO!!!§
SOOOOOON with Dr, Patrick Soon-Shiong's ROCKET-SHIP to the MOON!
TOO GOOD TO BE TRUE? TOO GOOD NOT TO!!!!!
GLTA!
KEYO =
What gives w/this shit, Buck? Just hype? I could push soda if you paid me $220K a year! I've been busy w/some other things, it's winding down. Gonna call him relentlessly and start screaming some obscenities. BS! I'm down 80% on 1.5M. He played the perfect con game. Hired AD just to get the pps up so homeboy could cash-out? That SOB...whyioutta
Good luck gdog!
It's been awfully quiet last 2 weeks...
Who can explain how PSS acquired the shares jointly held by Cal Cap Partners & Themba? These are the filings up till 04/08/11
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001360773&type=&dateb=&owner=include&count=40
Then on 04/11/11 Cal Cap Equity reports:
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001517764&type=&dateb=&owner=include&count=40
Jeez, it says right there, "Cal Cap Equity is an Investment Vehicle for Patrick Soon-Shiong. You don't think he's going to cash-in on that investment someday?
Halloween would be sweet! Can't you just see him, lab coat and freaky hair...vial of serum in his hand? Standing in the lobby of Willshire? I can't believe this stock exists. I got a little more powder from the stupid frickin' ELRA thing today. Gonna slap Pockets tomorrow! BTW, I think Pockets is the Doc. This is why:
PSS Recieving UCLA Award Thursday.
Perhaps he'll say, "..and NantWorks is pleased to announce..."
Auditors still walking to CT?
Check your DD...itsallthere.
Oh God, this has turned into IFCR
Ted Eppel is on the BOD at §ECDC. Correct? He also sits on the Board of New Leaf Brands, Inc. §NLEF. That extremely promising company has given investors the silent, BS, carrot-on-a-stick treatment for 6 months. No pulse.
If anyone on this board happens to get through to 'ol Ted kindly ask him WTF is going on w/NLEF while you bitch at him for this diluted mess...please?
Thank you, sorry to troll.
Edward(Ted) H. Eppel
VP - LPS Industries
800.275.6577
I disagree.
KEYO
Please explain outdated. Does that mean no longer accurate? The company was reinstated and then dissolved as a point of procedure to affect a Reverse Triangular Merger. Corporate actions such as mergers and acquisitions cannot be performed on a Revoked Entity. Any two-bit Accountant could tell you that! The network that Keyon had acquired was legacy broadband wireless and voip. TW informed PSS that in order to effect his vision he would need to use a level-1 secure, fibre optic backbone. So he bought the National Lambda Rail! He sold the KeyOn assets, the infrastructure. In fact, he was so exited to be working with a man of TW's prowess, he gave him a piece of the pie. It's called NantTronics. But he kept the KeyOn Corporate Shell. If he did not have plans for the company's future he would have just sold KeyOn; lock, stock and barrel! He has 80% interest in KEYO! Post a link that proves otherwise. NEOM went SOUTH and PSS moved on. I despise verbal tennis matches and this is SURELY getting tiring. But if you insist...
§KEYO§ =
§Back to the facts:§
http://www.sec.gov/Archives/edgar/data/1335294/000114420411036857/v226300_sc13da.htm
(a) - (b) Cal Equity and Dr. Soon-Shiong, as the sole member of Cal Equity, may be deemed to share beneficial ownership of 30,081,734 shares of Common Stock by virtue of Cal Equityโs direct ownership of 16,315,068 shares of Series A Preferred Stock, warrants to purchase 10,300,000 shares of Series A Preferred Stock and the Convertible Note Due 2012, which was initially convertible into 3,466,666 shares of Series A Preferred Stock. Such ownership represents 79.2% of the voting power and 55.9% of the economic interest of the Company. The foregoing is based on each share of Series A Preferred Stock being convertible into one share of Common Stock and each share of Series A Preferred Stock having the right to three votes for each share of Common Stock into which such shares of Series A Preferred Stock could then be converted.
Structured voting rights are better than rumors!
KEYO
§KEYO HUGE IPO ROUMOR!!!!§
GET ON BOARD!!! AN IPO WILL PRICE AT LEAST $4/SH!!!
READ PREVIOUS POSTS!! IPOIPOIPOIPOIPOIPOIPOIPOIPO
§KEYO GO! IPO!
Great find, S3lfMade! What did you get from your DD?
KEYO
Copping 45K on Friday was really sweet! 4.262% and counting! That will help with the accredited investor designation come 2015. Then my $250,000 equity can go toward the APO!!! Goodbye Princeton tuition! Yea kid, you can go for the Doctorate!
HA HA HA! Losing $7000 on stinky NEOM won't matter squat!
HA HA HA! I'm IN!
KEYO
Happy Halloween!
Yes. Although I am not 100% sure the NASDAQ adopted the resolution, NantWorks financials and the PIPE/RD offering would preclude the requirement. Realise that benefical owners' personal net worth is factored in. PSS = $12B! The NASDAQ would welcome NantWorks with MORE than open arms!
"Scrutiny" is not a concern here! NantWorks does not need to concern itself with "proving" itself!
That is not the nature of a Rocket-Ship!
KEYO
There are generally three types of Reverse Mergers with OTC Shell Companies. From least desirable to most from the standpoint of the shell investor:
1) A Shell Company with large (>1B) OS and a Private Company with little to no Assets.
This includes the majority of OTC shell stock/RM plays and all those focused on in the SEC's Operation Shell Expell
Almost ALWAYS includes a Reverse-Split of the Common Shares to reduce Stockholders Of Record and Common Shareholders and often a Post-Merger Forward-Split of the Authorized Shares to further dilute the Shell Holders.
Pure-Play opportunities that require the exit of position at a precise time.
2) A Shell Company with large (>1B) OS and a Private Company with growing Assets.
This is the type of RM that 1) above tries to imply, but usually is not. These are normally legitimate RMs for the typical RM advantages.
Almost ALWAYS includes a Reverse-Split of the Common Shares to reduce Stockholders Of Record and Common Shareholders. Requires a time commitment from the Shell Investor.
Long opportunities that can pay huge returns after the holding period.
3) A "Clean" Shell Company with a small (<250M) OS and a Private Company with substantial Assets (>$100M).
These types of RMs are almost never seen on the OTC and seldom on Exchanges.
Classified as Once-In-A-Lifetime opportunities, these rarities are an enigma.
Instant Millionaire opportunities that offer enormous Short-Term gains while establishing Legacy Investment Portfolios.
And then there's...
4) KEYO
§KEYO =
§KEYO RTM In Progress!!!§
If you have done your DD, or at least read the recent posts on this board, and are not convinced that a Reverse Triangular Merger is in progress here...read this book:
http://books.google.com/books?id=Br5DHzRaI98C&pg=PA126&lpg=PA126&dq=firm+commitment+vs+pipe%27&source=bl&ots=hC3BksjQmo&sig=PWpj86OCMs9WLaezZMepKlDolwY&hl=en&sa=X&ei=NvNLVJCVJ5WwyASDg4CQAg&ved=0CFcQ6AEwCA#v=onepage&q=firm%20commitment%20vs%20pipe%27&f=false
NANTs Shelf Registration will be included in the HUMONGOUS Super-8K. Six months of seasoning on the OTCQB and a Registered Direct Offering upon listing on the NASDAQ.
If you own KEYO shares, you are going to be one lucky SOB!
Happy Halloween!
Under the rules, the reverse merger company generally would be exempt from these special requirements if it is listing in connection with a substantial firm commitment underwritten public offering, or the reverse merger occurred long ago so that at least four annual reports with audited financial information have been filed with the SEC.
http://www.sec.gov/news/press/2011/2011-235.htm
KEYO
What benefits does a reverse triangular merger have? It keeps a target company's contracts with desirable customers. In a forward or direct merger, the target ceases to exist and contracts may be subject to termination.
Reverse triangular mergers have disadvantages too. It is more difficult to structure the deal as a tax-free reorganization under IRS rules. Deal consideration received by target stockholders in a triangular merger usually consists of voting stock of the acquirer. For a reverse merger to qualify as a tax-free reorganization, at least 80 percent of the total consideration must be voting stock of the acquiring company.
A reverse triangular merger allows the acquirer to complete an acquisition without obtaining the unanimous vote of the target company's stockholders; limit the acquirer's exposure to the target company's liabilities by holding the target company as a subsidiary; and obtain desirable target company contracts that are subject to termination if the target company fails to survive the transaction.
A reverse triangular merger is also attractive to target company stockholders because the buyer acquires all of the liabilities of the target and the transaction can often be structured to be nontaxable at the time of the acquisition.
http://www.bizjournals.com/boston/blog/mass-high-tech/2002/12/forward-or-reverse-whats-involved-in-a-merger.html?page=all
§KEYO
Taking a company public via a traditional initial public offering can be a great way to raise not only capital but the public profile of your business. But going public can be a complex, expensive, and time-consuming process. A shortcut exists, however, that may offer an appropriate alternative to an IPO for some companies.
With a reverse merger, a private company can acquire a public company that has gone dormant and assume the public company status of the business it acquires. A dormant or โshellโ public company is one that is still listed on a stock exchange but has no assets, usually due to a sale or a bankruptcy.
Reverse mergers offer certain benefits: They can be accomplished relatively quickly and inexpensively compared to a traditional IPO, and they involve less regulatory red tape. They donโt raise nearly as much capital as an IPO, however, at least not initially. This usually makes reverse mergers better for private companies that arenโt desperate to raise large amounts of cash quickly but rather have the capability to grow substantially on their own in the future.
Reverse mergers also provide a higher degree of certainty to business owners than IPOs because they arenโt dependent on market conditions. An IPO can be canceled at the last minute if market conditions change drastically, wiping out a year or more of preparation, but reverse mergers arenโt subject to such volatility.
Charts don't lie, I continue to buy:
KEYO
"So refreshing!" (as the paid pumpers would say) to hear you say that. Almost 50% of the float locked? And still, the only 13/D we have is:
http://www.sec.gov/Archives/edgar/data/1335294/000114420411036857/v226300_sc13da.htm
The Good Doctor is very clear about which companies he holds interest in and which he does not.
KEYO
Should we start spamming the boards and get a good pump going here?
KEYO
WTF!?
I see nothing new. All the Ip info is the same. It's JAB's doing. I believe my ISP is through JAB lines here in CO.
Dropped quite a bit today. I scored some cheapies, and dropped my bid to 10K@.0505. That was last trade but I did not get filled. I hate it when they do that.."screw-you retail!" Oh well, we can play again tomorrow. I hope!
KEYO...BOO!
KEYO = NANT = Io T
A read through this wiki put's you right inside the Good Doctor's head. Don't get lost!
http://en.wikipedia.org/wiki/Internet_of_Things
§KEYO
Patrick Soon-Shiong is remaking the US healthcare system. Here's how
Science
09 August 13 by Joao Medeiros
Over the past five years, LA-based surgeon and businessman Patrick Soon-Shiong has ploughed over $700 million (£450 million) into about 50 companies to remake the US healthcare system. He heads NantWorks, an umbrella organisation created in 2011 that includes businesses conducting research in semiconductor technology, supercomputing, artificial intelligence and cancer-drug discovery.
It's the 60-year-old South-African-born Chinese-American CEO's latest in a long list of ambitious projects. In 1993, he performed the first human islet cell transplant in diabetic patients. He developed Abraxane, a cancer drug wrapped in a coating of nanoparticles that allow the medicine to be delivered inside the tumour. By 2008, he had already founded and sold two multibillion-dollar pharmaceutical companies. According to Soon-Shiong, medicine has made dramatic advances, but its delivery has lagged behind. The key to that change is digital technology. He talks to Wired's Start editor João Medeiros about the future of his groundbreaking work.
In January, you announced the foundation of yet another company, NantOmics (part of NantWorks), to investigate cancer treatments based on knowledge that you developed in the 90s.
Yes, I was working with stem cells as part of a Nasa programme. We realised that the science of stem-cell proliferation was also fundamental to cancer cells when cancer enters the phase of metastasis. I thought there might be a unifying biology between stem-cell differentiation and cancer metastasis: the same protein could be involved in both processes. The idea that all cancer cells, regardless of type, would absorb this protein led us to create a nanoparticle of the protein and place a drug inside it. It was very difficult to convince the oncologists that we would be able to treat all tumour types. It was a magic portal to the tumour cell. We've proven in clinical trials that this is the case. The drug Abraxane is now approved in breast cancer and lung cancer in the United States, China and Europe. It has also succeeded in treating melanoma and pancreatic cancer.
Your approach to cancer research is not just limited to drugs. You're also looking at the level of the genome and the proteome [the proteins expressed by the genome].
We need a genomic and proteinomic understanding of the disease in a personalised way. When I started calculating the amount of data and computer power needed, I discovered they were an impossibility at the time. We needed to accommodate yottabytes. You have in the US around two million new diagnoses of cancer a year, and 13 million survivors, so you have about 10,000 patients that require analysis every day. That's about five petabytes that need to be transmitted and computed on a daily basis.
That's an immense computational challenge.
It's a deluge of big data. You also need an algorithm that takes all the various analyses together - genome, proteome, known pathways and networks of protein systems and patient's clinical data. You also need a way to transport this in a secure cloud to the doctor and the patient in the clinic. That was our goal and we just announced the first complete computation for more than 3,000 patients. The largest analysis ever done. We completed the transmission and computation in 69 hours -- about 47 seconds per genome.
All this adds up to the concept of convergence that underpins your vision for healthcare.
Yes. It's the convergence of semiconductors, of machine vision, supercomputing algorithms, fibre networks and medical connectivity. Collecting all the clinical data and the vital signs of a single patient throughout the course of their life didn't exist before because there was no interoperability between electronic medical records and medical devices to capture your blood pressure, your heart rate and vital signs -- what I call the human signal engine. I funded a programme which developed ways of interacting with thousands of medical devices to capture the human signal engine. Our supercomputer for the human genome has been completed and we can now complete the bioinformatics of the cancer mutation in 47 seconds rather then the 11 weeks that it currently takes. What excites me is that these systems are in the cloud, connected by our dedicated secure fibre network spanning the country.
Artificial intelligence is also a big component of your project.
We are now building a human cognition engine in the form of a smartphone. We have developed the ability to recognise physical objects in the real world and also unlock information from the internet thereby creating what I call "augmented intelligence".
That's a description of your image-recognition app, iD.
Yes, iD is a machine vision and sensor browser for the physical world. That's what we have been working on with Coca-Cola, Verizon, Bank of America and Disney to launch content when an image is recognised. We've also released an app called LookTell Recognizer for the blind that recognises images and tells the user what it is. And we created an app, called DreamPlay, that recognises physical objects and creates an augmented reality based on that image.
Your vision with NantWorks isn't just limited to healthcare.
We're also interested in wellbeing. When we harness that power of convergence, we can achieve what was impossible before. Every patient is a consumer and every consumer is a potential patient. What NantWorks is doing is building the world the way Da Vinci saw it, and augmenting every frame a human being sees as they work, live and play.